Exhibit 99.29
PyroGenesis Canada Inc.
Condensed
Interim Financial Statements
Three months ended March 31, 2020 and 2019
(Unaudited)
CONDENSED INTERIM FINANCIAL STATEMENTS
The accompanying unaudited financial statements of PyroGenesis Canada Inc. have been prepared by and are the responsibility of the Company’s management. The Company’s independent auditor has not performed a review of these unaudited condensed interim financial statements for the period ended March 31, 2020
PyroGenesis Canada Inc.
Condensed Interim Statements of Financial Position
(unaudited)
March 31, 2020 | December 31, 2019 | |||||||
$ | $ | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash | 1,139,416 | 34,431 | ||||||
Accounts receivable [note 5] | 210,498 | 210,540 | ||||||
Costs and profits in excess of billings on uncompleted contracts and projects [note 6] | 167,905 | 122,980 | ||||||
Investment tax credits and government wage subsidy receivable [note 7] | 907,550 | 709,395 | ||||||
Deposits | 451,416 | 150,322 | ||||||
Prepaid expenses | 70,505 | 96,886 | ||||||
Total current assets | 2,947,290 | 1,324,554 | ||||||
Non-current assets | ||||||||
Inventories | 10,068 | 10,068 | ||||||
Deposits | 187,655 | 178,105 | ||||||
Strategic investments [note 8] | 1,117,330 | 1,609,354 | ||||||
Property and equipment | 2,069,496 | 1,977,481 | ||||||
Right of use assets | 3,653,404 | 3,742,769 | ||||||
Intangible assets | 811,675 | 736,898 | ||||||
Total assets | 10,796,918 | 9,579,229 | ||||||
Liabilities | ||||||||
Current liabilities | ||||||||
Accounts payable and accrued liabilities [note 9] | 5,278,093 | 4,913,155 | ||||||
Billings in excess of costs and profits on uncompleted contracts and projects [note 10] | 4,575,979 | 3,084,657 | ||||||
Term loans [note 11] | 528,667 | 496,000 | ||||||
Current portion of long-term debt | 295,000 | 284,956 | ||||||
Current portion of lease liabilities | 141,990 | 139,529 | ||||||
Convertible debentures [note 11] | 3,284,671 | 2,898,358 | ||||||
Total current liabilities | 14,104,400 | 11,816,655 | ||||||
Non-current liabilities | ||||||||
Long-term debt | - | - | ||||||
Lease Liabilities | 3,808,419 | 3,845,497 | ||||||
Convertible debentures [note 12] | 108,360 | - | ||||||
Total liabilities | 18,021,179 | 15,662,152 | ||||||
Shareholders’ deficiency [note 13] | ||||||||
Common shares and warrants | 47,820,219 | 47,073,243 | ||||||
Contributed surplus | 6,450,021 | 6,679,730 | ||||||
Equity portion of convertible debentures [note 12] | 500,182 | 401,760 | ||||||
Deficit | (61,994,683 | ) | (60,237,656 | ) | ||||
Total shareholders’ deficiency | (7,224,261 | ) | (6,082,923 | ) | ||||
Total liabilities and shareholders’ deficiency | 10,796,918 | 9,579,229 |
Going concern disclosure, related party transactions, contingent liabilities, subsequent events [notes 1(b), 17, 19, 22]
Approved on behalf of the Board: | |
[Signed by P. Peter Pascali] P. Peter Pascali | [Signed by Michael Blank] Michael Blank |
3
PyroGenesis Canada Inc.
Condensed interim Statements of Comprehensive Loss
(unaudited)
Three months ended March 31, | ||||||||
2020 | 2019 | |||||||
$ | $ | |||||||
Revenues [note 4] | 718,908 | 736,443 | ||||||
Cost of sales and services [note 15] | 451,494 | 644,285 | ||||||
Gross Profit | 267,414 | 92,158 | ||||||
Expenses (income) | ||||||||
Selling, general and administrative [note 15] | 1,276,593 | 1,330,005 | ||||||
Research and development | 23,088 | 95,774 | ||||||
Net finance costs [note 16] | 232,736 | 251,498 | ||||||
1,532,417 | 1,677,277 | |||||||
Net loss from operations | (1,265,003 | ) | (1,585,119 | ) | ||||
Changes in fair market value of strategic investments | 492,024 | (706,196 | ) | |||||
Net loss and comprehensive loss | (1,752,027 | ) | (878,923 | ) | ||||
Basic and diluted loss per share | (0.01 | ) | (0.01 | ) | ||||
Weighted average number of common shares - basic and diluted | 142,285,283 | 133,595,204 |
The accompanying notes form an integral part of the condensed interim financial statements.
4
PyroGenesis Canada Inc.
Condensed Interim Statements of Changes in Shareholders’ (Deficiency) Equity
(unaudited)
Number of Class A common shares | Class A common shares and warrants | Contributed | Equity portion of convertible debentures | Deficit | Total | |||||||||||||||||||
$ | $ | $ | $ | $ | ||||||||||||||||||||
Balance - December 31, 2019 | 141,303,451 | 47,073,243 | 6,679,730, | 401,760 | (60,237,656 | ) | (6,082,923 | ) | ||||||||||||||||
Share issued on exercise of stock options | 1,488,000 | 746,976 | (300,576 | ) | - | - | 466,400 | |||||||||||||||||
Share-based payments | - | - | 70,867 | - | - | 70,867 | ||||||||||||||||||
Equity component of convertible debentures issued | - | - | - | 98,422 | - | 98,422 | ||||||||||||||||||
Net loss and comprehensive loss | - | - | - | - | (1,757,027 | ) | (1,757,027 | ) | ||||||||||||||||
Balance – March 31, 2020 | 142,791,451 | 47,820,219 | 6,450,021 | 500,182 | (61,994,683 | ) | (7,224,261 | ) | ||||||||||||||||
Balance - December 31, 2018 | 133,501,051 | 42,863,456 | 6,795,274 | 401,760 | (51,066,540 | ) | (1,006,050 | ) | ||||||||||||||||
Private placement | 97,400 | 62,292 | - | - | - | 62,292 | ||||||||||||||||||
Share-based payments | - | - | 34,484 | - | - | 34,484 | ||||||||||||||||||
Net loss and comprehensive loss | - | - | - | - | (878,923 | ) | (878,923 | ) | ||||||||||||||||
Balance – March 31, 2019 | 133,598,451 | 42,925,748 | 6,829,758 | 401,760 | (51,945,463 | ) | (1,788,197 | ) |
The accompanying notes form an integral part of the condensed interim financial statements.
5
PyroGenesis Canada Inc.
Condensed Interim Statements of Cash Flows
(unaudited)
Three months ended March 31, | ||||||||
2020 | 2019 | |||||||
$ | $ | |||||||
Cash flows provided by (used in) | ||||||||
Operating activities | ||||||||
Net loss | (1,757,027 | ) | (878,923 | ) | ||||
Adjustments for: | ||||||||
Share-based payments | 70,867 | 34,484 | ||||||
Depreciation on property and equipment | 10,056 | 48,149 | ||||||
Depreciation of right-of-use assets | 89,365 | 109,672 | ||||||
Amortization of intangibles assets | 6,813 | 4,779 | ||||||
Finance costs | 232,736 | 251,498 | ||||||
Change in fair value of investments | 492,024 | (706,196 | ) | |||||
(855,166 | ) | (1,136,537 | ) | |||||
Net change in non-cash operating working capital items [note 15] | 1,122,234 | 1,154,794 | ||||||
267,068 | 18,257 | |||||||
Investing activities | ||||||||
Additions to inventories | - | (18,767 | ) | |||||
Purchase of property and equipment | - | (115,909 | ) | |||||
Variation of deposits | (9,550 | ) | 6,259 | |||||
(9,550 | ) | (128,417 | ) | |||||
Financing activities | ||||||||
Repayment of R&D loans [note 10] | - | (247,200 | ) | |||||
Repayment of convertible debenture [note11] | (354,000 | ) | - | |||||
Repayment of lease liabilities | (34,618 | ) | (52,494 | ) | ||||
Proceeds from convertible loan [note 11] | 903,000 | |||||||
Proceeds from issuance of shares – Private placement [note 12] | - | 62,292 | ||||||
Proceeds from issuance of shares upon exercise of stock options [note 12] | 446,400 | - | ||||||
Interest paid | (113,315 | ) | (155,569 | ) | ||||
847,467 | (392,971 | ) | ||||||
Net increase (decrease) in cash | 1,104,985 | (503,131 | ) | |||||
Cash - beginning of period | 34,431 | 644,981 | ||||||
Cash - end of period | 1,139,416 | 141,850 | ||||||
Supplemental cash flow disclosure | ||||||||
Non-cash transactions: | ||||||||
Purchase of property and equipment included in accounts payables | 102,071 | 39,277 | ||||||
Purchase of intangibles assets included in accounts payables | 81,591 | 46,509 | ||||||
Interest included in accounts payable | 32,614 |
The accompanying notes form an integral part of the condensed interim financial statements
6
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
1. Nature of operations and going concern disclosure
(a) Nature of operations
PyroGenesis Canada Inc. (the “Company”), incorporated under the laws of the Canada Business Corporations Act, was formed on July 11, 2011. The Company owns patents of advanced waste treatment systems technology and designs, develops, manufactures and commercialises advanced plasma processes and systems. The Company is domiciled at 1744 William Street, Suite 200, Montreal, Quebec. The Company is publicly traded on the TSX Venture Exchange under the Symbol “PYR”. During 2015, the Company received approval to trade on the OTCQB in the USA under the symbol “PYRNF”.
(b) Going concern
These condensed interim financial statements have been prepared on the going concern basis, which presumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.
2. Basis of preparation
(a) Statement of compliance
These condensed interim financial statements have been prepared in accordance with International Financial Reporting Standard (“IFRS”) as issued by the International Accounting Standards Board ("IASB"). These condensed interim financial statements do not include all of the necessary information required for full annual financial statements in accordance with IFRS and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2019.
These condensed interim financial statements were approved and authorized for issuance by the Board of Directors on July 16, 2020.
(b) Functional and presentation currency
These condensed interim financial statements are presented in Canadian dollars, which is the Company’s functional currency.
(c) Basis of measurement
These condensed interim financial statements have been prepared on the historical cost basis except for the investments which are accounted for at fair value.
3. Significant accounting judgments, estimates and assumptions
The significant judgments, estimates and assumptions applied by the Company’s in these condensed interim financial statements are the same as those applied by the Company in its audited annual financial statements as at and for the year ended December 31, 2019.
7
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
4. Revenues
The Company’s revenues from long-term contracts and sales of goods are generated primarily from DROSRITE™ related sales of $474,432 (2019 - $58,559), PUREVAP™ related sales of $17,965 (2019 - $94,077), Torch related sales of $87,944 (2019 - $139,813), and the development and support related to systems supplied to the U.S. Military $23,896 (2019 - $210,667).
Refer to note 20 for sales by geographic area and by product line.
Transaction price allocated to remaining performance obligations
As at March 31, 2020, revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) at the reporting date is $28,405,077. Revenue will be recognized as the Company satisfies its performance obligations under long-term contracts, which is expected to occur over the next 3 years.
5. Accounts receivable
Details of accounts receivable were as follows:
March 31, 2019 | December 31, 2019 | |||||||
$ | $ | |||||||
1 – 30 days | 55,640 | 71,423 | ||||||
31 – 60 days | 25,311 | 9,483 | ||||||
61 – 90 days | 6,485 | 17,753 | ||||||
Greater than 90 days | 30,376 | 5,469 | ||||||
Total trade accounts receivable | 117,812 | 104,128 | ||||||
Other receivables | 220,528 | 106,412 | ||||||
338,340 | 210,540 |
There is no allowance for expected credit losses recorded as at March 31, 2020 and December 31, 2019.
6. Costs and profits in excess of billings on uncompleted contracts and projects
As at March 31, 2020, the Company had three uncompleted contracts and projects with total billings of $155,441 which were less than total costs incurred and had recognized cumulative revenue of $323,346 since those contracts and projects began. This compares with five contracts with total billings of $89,256 which were less than total costs incurred and had recognized cumulative revenue of $212,236 as at December 31, 2019.
Changes in costs and profits in excess of billings on uncompleted contracts during the three months ended March 31, 2020 are explained by $21,211 recognized at the beginning of the year being transferred to accounts receivable, and $66,136 resulting from changes in the measure of progress.
8
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
7. Investment tax credits and government wage subsidy
As at March 31, 2020 investment tax credits related to qualifying projects from the provincial government were $70,313 (2019 - $709,395). The Company also recorded during the three months ended March 31, 2020 an amount of $127,842 (2019 - $Nil) as a government subsidy from Revenue Canada under the CEWS program.
8. Strategic investments
March 31, 2020 | December 31, 2019 | |||||||
$ | $ | |||||||
Beauce Gold Fields (“BGF”) shares – level 1 | 102,579 | 133,354 | ||||||
HPQ Silicon Resources Inc. (“HPQ”) shares - level 1 | 1,014,750 | 1,476,000 | ||||||
HPQ warrants – level 3 | - | - | ||||||
1,117,329 | 1,609,354 |
Investments in HPQ (TSXV: HPQ) comprise 18,450,000 common shares (18,450,000 - 2019) and 17,750,000 warrants (17,750,000 - 2019). 1,500,000 warrants have an exercise price of $0.25 with an expiry date of November 21, 2020 and the remaining 16,250,000 warrants have an exercise price of $0.17 with an expiry date of August 21, 2021.
Investment in BGF (TSXV: BGF) consists of 1,025,794 of common shares. The 1,025,794 common shares of BGF were received in December 2018 as dividend in kind from a spinoff of HPQ.
16,250,000 common shares of HPQ and 16,250,000 warrants of HPQ were purchased in cash ($1,950,000) in 2018. 2,500,000 common shares and 2,500,000 warrants were received in 2017 in lieu of payment of services rendered by the Company to HPQ. At the transaction dates, these non-monetary transactions were measured based on the fair value of the common shares and warrants received for a total amount of $320,000. A gain from initial recognition of the warrants of $24,017 ($62,214 – 2017) has been deferred off balance sheet until realised.
(“BGF”) shares – level 1 | HPQ shares – level 1 | (“HPQ”) Warrants - level 3 | ||||||||||||||||||||||
Quantity | $ | Quantity | $ | Quantity | $ | |||||||||||||||||||
Balance, December 31, 2018 | 1,025,794 | 102,579 | 21,350,000 | 1,281,000 | 18,750,000 | 310,537 | ||||||||||||||||||
Disposals | - | - | (2,900,000 | ) | (261,000 | ) | - | - | ||||||||||||||||
Expired warrants | - | - | - | - | (1,000,000 | ) | - | |||||||||||||||||
Change in the fair value | - | 30,775 | - | 456,000 | - | (310,537 | ) | |||||||||||||||||
Balance, December 31, 2019 | 1,025,794 | 133,354 | 18,450,000 | 1,476,000 | 17,750,000 | - | ||||||||||||||||||
Change in the fair value | - | (30,775 | ) | - | (461,250 | ) | - | - | ||||||||||||||||
Balance, March 31, 2020 | 1,025,794 | 102,579 | 18,450,000 | 1,014,750 | 17,750,000 | - |
9
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
9. Accounts payable and accrued liabilities
March 31, 2020 | December 31, 2019 | |||||||
$ | $ | |||||||
Accounts payable | 3,159,356 | 2,780,628 | ||||||
Accrued liabilities | 1,954,663 | 1,866,822 | ||||||
Accounts payable to the controlling shareholder | 164,074 | 214,470 | ||||||
Accounts payable to a trust beneficially owned by the controlling shareholder | - | 51,234 | ||||||
5,278,093 | 4,913,155 |
10. Billings in excess of costs and profits on uncompleted contracts
The amount to date of costs incurred and recognized profits less recognized losses for construction projects in progress amounted to $5,126,249 (2019 - $4,612,082).
Payments to date received were $7,752,228 and $1,950,000 of deposits on contract in progress (2019 - $5,746,739 in cash and $1,950,000 of other assets).
Changes in billings in excess of costs and profits on uncompleted contracts during the three months ended March 31, 2020 are explained by $19,475 recognized as revenue, and an increase of $1,510,797 resulting from cash received excluding amounts recognized as revenue.
11. Term loans
Other Term Loans¹ | 2019 SR&ED Tax Credit loan² | 2018 SR&ED Tax Credit loan³ | 2017 SR&ED Tax Credit loan4 | Total | ||||||||||||||||
$ | $ | $ | $ | $ | ||||||||||||||||
Balance, December 31, 2018 | - | - | - | 247,200 | 247,200 | |||||||||||||||
Additions | 115,200 | 247,500 | 214,000 | - | 576,700 | |||||||||||||||
Conversion option | (12,800 | ) | - | - | - | (12,800 | ) | |||||||||||||
Financing costs | - | (63,558 | ) | (54,955 | ) | - | (118,513 | ) | ||||||||||||
Accretion | 8,533 | 1,389 | 40,691 | - | 50,613 | |||||||||||||||
Repayment | - | - | - | (247,200 | ) | (247,200 | ) | |||||||||||||
Balance, December 31, 2019 | 110,933 | 185,331 | 199,736 | - | 496,000 | |||||||||||||||
Accretion | 3,200 | 15,803 | 13,664 | - | 32,667 | |||||||||||||||
Balance, March 31, 2020 | 114,133 | 201,134 | 213,400 | - | 528,667 |
1 maturing May 1, 2020 bearing interest rate of 8% per annum payable at the maturity date.
2 maturing December 23, 2020 bearing interest rate of 16.68% payable at the issuance.
3 maturing April 3, 2020 bearing interest rate of 16.68% payable at the issuance.
4 matured September 30, 2018 bearing interest rate of 18% (effective interest rate 23%), repaid February 2019.
10
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
11. Term loans (continued)
On December 23, 2019, the Company entered into a SR&ED tax credit loan of $247,500 bearing interest at a rate of 16.68% and fees totaling $22,375 paid at the issuance of the loan. The loan was discounted using the effective interest method. The effective interest rate on the loan is 25.68%. The loan is secured by the 2019 investment tax credit receivable and is repayable on December 22, 2020.
On March 25, 2019, the Company entered into a SR&ED tax credit loan of $214,000 bearing interest at a rate of 16.68% and fees totaling $19,260 paid at the issuance of the loan. The loan was discounted using the effective interest method. The effective interest rate on the loan is 25.68%. The loan is secured by the 2018 investment tax credit receivable and is repayable on April 2, 2020.
The SR&ED tax credit loans are financing, in the form of loans, with respect to the Company’s scientific research and experimental development tax credits ("SR&ED Tax Credits"). The principal of the loans is subject to holdback to be disbursed upon reception of notice of assessment. The principal of the loans is subject to repayment at the earlier of (a) receipt of the SR&ED Tax Credits refund or (b) the maturity date. The SR&ED Tax Credits loans agreement provides for automatic renewal of twelve months if loan is not paid at maturity. As at March 31, 2020, the amount available under the term loan financing agreement totals $461,500 (2019 – $461,500).
Pursuant to each financing, the Company granted the lender a security interest and movable hypothec on all of its assets excluding its intellectual property but including a first rank claim on the refundable portion of its SR&ED Tax Credits for each of the fiscal years ended December 31, 2018, of $274,921 and 2019 of $434,474.
In Q1-2020, the Company recorded investment tax credits receivable of $70,313 (Q1-2019 - $67,895), of which an amount of $30 (Q1-2019 - $Nil) was recorded against property and equipment, $20,629 ( Q1–2019 - $36,071) was recorded against cost of sales and services, $42,154 (Q1-2019 - $24,324) against research and development expenses and $7,500 (Q1-2019 - $7,500) against selling general and administrative expenses..
On May 1, 2019 the Company entered into loan agreements with unrelated individuals totaling $115,200 bearing interest at the annual rate of 8% payable at maturity, on May 1, 2020. The other term loans are unsecured and are convertible, at 10% discount, for a variable amount, of shares into any future private placement until maturity. The fair value of the debt instrument at inception was determined using the estimated cash flows discounted using a market rate of 20%. The residual amount of the non derivative liability of $12,800 associated with the conversion feature has been recorded in accounts payable and accrued liabilities.
11
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
12. Convertible debentures
March 31, 2020 | December 31, 2019 | |||||||
$ | ||||||||
2018 Convertible debenture | 2,586,963 | 2,898,358 | ||||||
Convertible loan | 806,068 | - | ||||||
3,393,031 | 2,898,358 | |||||||
Current portion | 3,284,671 | 2,898,358 | ||||||
Long-term portion | 108,360 | - |
Convertible loan
On March 18, 2020, the Company closed a $903,000 non-brokered secured convertible loan at 12% per annum, with a trust whose beneficiary is the controlling shareholder and CEO of the Company. The Loan bears interest at the rate of 12% per annum, with interest payable in cash on a quarterly basis in arrears and matures September 17, 2021. The convertible debentures may be converted before maturity, in whole at anytime or in part from time to time at a conversion price of $0.25 at the option of the lender. The is secured by a deed of hypothec charging on the universalities of movable assets.
The Convertible loan is a compound financial instrument and the total proceeds of the issuance was allocated between a liability for the debenture and an equity component for the conversion feature. The fair value of the debt liability component at inception was determined using estimated future cash flows discounted using a market interest rate of 20%. The effective interest rate of the liability component is 21.55%. The residual amount representing the value of the conversion option equity component was classified in the shareholders’ (Deficiency) Equity.
At the issuance date, the Convertible loan was recorded as follows:
$ | ||||
Liability component | 804,578 | |||
Conversion option recognized in equity, net of transaction cost of $47,338 | 98,422 | |||
Net proceeds | 903,000 |
March 31, 2020 | ||||
Total | ||||
$ | ||||
Liability component at issuance | 804,578 | |||
Effective interest accretion | 1,490 | |||
Balance, end of period | 806,068 |
12
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
12. Convertible debentures (continued)
Convertible debenture
On April 2, 2018, the Company completed a $3,000,000 non-brokered private placement of 9.5% secured convertible debentures (the “2018 Convertible Debenture”). The 2018 convertible debentures bear interest at the rate of 9.5% per annum, with interest payable in cash on a quarterly basis, and mature on March 29, 2020. Each Debenture is convertible into common shares of the Company at a conversion price of $0.80 per common share. The 2018 convertible debentures may be redeemed before maturity, in whole at anytime or in part from time to time at the option of the Company. In the event the Company elects to redeem the debentures before the maturity date, the Company shall be required to pay all interest that otherwise would have accrued on the debentures up to the maturity date. The 2018 convertible debentures are secured by a hypothec on the universality of all of the property, rights and assets of the Company, present and future, movable and immovable, corporeal and incorporeal.
The 2018 Convertible Debenture is a compound financial instrument and the total proceeds of the issuance was allocated between a liability for the debenture and an equity component for the conversion feature. The fair value of the debt liability component at inception was determined using estimated future cash flows discounted using a market interest rate of 20%. The residual amount representing the value of the conversion option equity component was classified in the shareholders’ (Deficiency) Equity.
In connection with the convertible debenture, the Company paid finder fees in the amount of $180,000 to the agent. Total transaction costs amount to $315,702 and have been allocated between the liability and equity components. The effective interest rate of the liability component is 20.23%.
At the issuance date, the 2018 Convertible Debenture was recorded as follows:
$ | ||||
Debt component, net of transactions cost of $268,364 | 2,282,538 | |||
Conversion option recognized in equity, net of transaction cost of $47,338 | 401,760 | |||
Net proceeds | 2,684,298 |
On March 30, 2020, the Company reached an agreement to extend the maturity date of its $3,000,000 convertible debenture to June 30, 2020, from the original maturity date of March 29, 2020. Under the terms of the agreement, the Company redeemed $300,000 (representing 10% of the principal amount), paid a onetime accommodation fee of $54,000, and is no longer subject to any prepayment penalties going forward. The conversion features have not changed. The gain in the amount of $59,037 resulting from the revised amortised cost of the convertible debenture was recognised in loss presented against the accretion expense.
13
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
12. Convertible debentures (continued)
March 31, 2020 | December 31, 2019 | |||||||
Total | ||||||||
$ | $ | |||||||
Balance, beginning of period | 2,898,358 | 2,527,241 | ||||||
Effective interest accretion | 101,642 | 371,117 | ||||||
3,000,000 | 2,898,358 | |||||||
Repayment of 2018 Convertible Debenture in cash | (300,000 | ) | - | |||||
Finance fees | (54,000 | ) | - | |||||
Gain on refinancing | (59,037 | ) | ||||||
Balance, end of period | 2,586,963 | 2,898,358 |
13. Shareholders’ deficiency
Common shares and warrants
Authorized:
The Company is authorized to issue an unlimited number of Class A common shares without par value.
Issuance of shares
The following table sets out the activity in stock options during the three months ended March 31, 2020:
Number of options | Weighted average exercise price | |||||||
$ | ||||||||
Balance – December 31, 2019 | 8,438,000 | 0.37 | ||||||
Granted | 100,000 | 0.45 | ||||||
Exercised | 1,488,000 | 0.30 | ||||||
Balance, March 31, 2020 | 7,050,000 | 0.33 |
14
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
13. Shareholders’ deficiency (continued)
As at March 31, 2020, the outstanding options, as issued under the stock option plan to directors, officers, employees and consultants for the purchases of one common share per option, are as follows:
Number of stock options March 31, 2020 | Exercise price per option (1) | Expiry date | ||||||||||
$ | ||||||||||||
September 25, 2016 | 3,000,000 | 0.18 | Sep 25, 2021 | |||||||||
October 25, 2016 | 100,000 | 0.19 | Oct 25, 2021 | |||||||||
November 3, 2017 | 2,600,000 | 0.58 | Nov 3, 2022 | |||||||||
February 9, 2018 | 200,000 | 0.60 | Feb 9, 2023 | |||||||||
May 10, 2018 | 250,000 | 0.52 | May 10, 2023 | |||||||||
July 3, 2018 | 300,000 | 0.51 | July 3, 2023 | |||||||||
October 29, 2018 | 100,000 | 0.52 | Oct 29, 2023 | |||||||||
September 29, 2019 | 400,000 | 0.51 | Sep 29, 2024 | |||||||||
January 2, 2020 | 100,000 | 0.45 | Jan 02, 2025 | |||||||||
7,050,000 | 0.33 |
On January 2, 2020, the Company granted 100,000 stock options to a director of the Company. The stock options have an exercise price of $0.45 per common share, 100% vested at grant date and are exercisable over a period of 5 years. The fair value of the stock options was estimated at $0.34 per option by applying the Black-Sholes option pricing model.
15
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
13. Shareholders’ deficiency (continued)
Share purchase warrants
The following table reflects the activity in warrants for the three months ended March 31, 2020 and the number of issued and outstanding share purchase warrants at December 31, 2019:
Number of warrants December 31, 2019 | Issued | Exercised | Number of warrants March 31, 2020 | Price per warrant | Expiry date | |||||||||||||||||||
$ | ||||||||||||||||||||||||
Issuance of units – April 19, 2018 | 3,108,333 | - | - | 3,108,333 | 0.85 | Apr 19, 2020 | ||||||||||||||||||
Issuance of broker warrants – April 19, 2018 | 74,000 | - | - | 74,000 | 0.85 | Apr 19, 2020 | ||||||||||||||||||
Issuance of units – April 20, 2018 | 3,385,715 | - | - | 3,385,715 | 0.85 | Apr 20, 2020 | ||||||||||||||||||
Issuance of units – September 28, 2018 | 3,448,276 | - | - | 3,448,276 | 0.58 | Jan 28, 2021 | ||||||||||||||||||
Issuance of units – October 19, 2018 | 1,500,750 | - | - | 1,500,750 | 0.58 | Feb 13, 2021 | ||||||||||||||||||
Issuance of units – December 17, 2018 | 2,244,367 | - | - | 2,244,367 | 0.85 | Dec 18, 2020 | ||||||||||||||||||
Issuance of units – May 15, 2019 | 2,996,500 | - | - | 2,996,500 | 0.85 | May 15, 2021 | ||||||||||||||||||
Issuance of units – May 24, 2019 | 2,024,500 | - | - | 2,024,500 | 0.85 | May 24, 2021 | ||||||||||||||||||
Issuance of units – June 19, 2019 | 1,000,000 | - | - | 1,000,000 | 0.85 | Jun 19, 2021 | ||||||||||||||||||
Issuance of units – October 25, 2019 | 225,000 | - | - | 225,000 | 0.75 | Oct 25, 2021 | ||||||||||||||||||
20,007,441 | - | 20,007,441 | 0.78 |
14. Supplemental disclosure of cash flow information
Net changes in non-cash components of operating working capital
2020 | 2019 | |||||||
$ | $ | |||||||
Decrease (increase) in: | ||||||||
Accounts receivable | (127,800 | ) | 420,612 | |||||
Costs and profits in excess of billings on uncompleted contracts | (44,925 | ) | 184,852 | |||||
Investment tax credits receivable | (70,313 | ) | 4,099 | |||||
Deposits | (301,094 | ) | 434,324 | |||||
Prepaid expenses | 26,381 | (30,564 | ) | |||||
Increase (decrease) in: | ||||||||
Accounts payable and accrued liabilities | 148,663 | 2,103,997 | ||||||
Billings in excess of costs and profits on uncompleted contracts | 1,491,322 | (1,267,753 | ) | |||||
1,122,234 | 1,849,567 |
16
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
15. Other information
The aggregate amortization of intangible assets expense for the three months ended March 31, 2020 was $6,813 (2019 - $20,133) and was recorded in cost of sales and services.
Depreciation on property and equipment amounted to $10,056 and depreciation on right of use assets amounted to $89,365 for the three months ended March 31, 2020 (2019 $48,419 and $109,672 respectively) and is recorded in selling, general and administrative. Employee benefits totaled $1,492,034 in the three months ended March 31, 2020 (2019 - $1,463,634) and include share-based compensation of $70,867 (2019 - $34,484).
The Company has been awarded various grants during the three months period, which were recognized when they became receivable. The grants, received in Q1, 2020, are unconditional and amounted to $218,636 (2019 - $132,014). An amount of $206,136 (2019 - $109,976) was recorded as a reduction to the related expenses in research and development and an amount of $12,500 (2019 - $22,038) was recorded as a reduction to the related expenses in selling, general and administrative.
16. Net finance costs:
Three months ended March 31, | ||||||||
2020 | 2019 | |||||||
$ | $ | |||||||
Finance costs | ||||||||
Interest and fees on convertible debentures | 75,120 | 71,250 | ||||||
Interest accretion of convertible debentures | 44,096 | 89,798 | ||||||
Interest on term loans | 34,965 | 73,224 | ||||||
Interest on lease liabilities | 63,235 | 8,132 | ||||||
Interest accretion on promissory notes | 14,458 | |||||||
Other interest expenses | 862 | 9,094 | ||||||
Net finance costs | 232,736 | 251,498 |
17. Related party transactions
During the three months ended March 31, 2020, the Company concluded the following transactions with related parties:
The Company entered into a lease agreement for rent of a property with a trust whose beneficiary is the controlling shareholder and CEO of the Company. As at March 31, 2020 the carrying amount of the right-of-use asset and lease liabilities are $1,141,649 and $1,184,669, respectively.
An amount of $68,047 was charged by a trust whose beneficiary is the controlling shareholder and CEO for rent and property taxes (rent and property taxes of $66,679 was charged in 2019). A balance due of $Nil (2018 - $51,134) is included in accounts payable and accrued liabilities.
17
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
17. Related party transactions (continued)
An amount of $115,581 was paid as a deposit for rent to a trust whose beneficiary is the controlling shareholder and CEO of the Company (December 31, 2019 – $Nil), of this amount $100,527 is included in deposits.
A balance due to the controlling shareholder and CEO of the Company amounted to $164,074 (December 31, 2019 - $214,470) for expense report, salary and vacation payables and is included in accounts payable and accrued liabilities as at March 31, 2019.
As at March 31, 2020, an amount of $4,413 (December 31, 2019 - $7,427), of interest payable and an accretion amount of $10,045 (December 31, 2019 - $12,946), were accrued on the loan of $295,000 from the controlling shareholder and CEO of the Company and are included in accounts payable and accrued liabilities.
As at March 31, 2020, an amount of $3,870 (December 31, 2019 - $Nil), of interest payable and an accretion amount of $5,360 (December 31, 2019 - $Nil), were accrued on a convertible loan of $903,000 from a trust whose beneficiary is the controlling shareholder and CEO of the Company and are included in accounts payable and accrued liabilities.
The key management personnel of the Company are the members of the Board of Directors and certain officers. Total compensation to key management consisted of the following:
2020 | 2019 | |||||||
$ | $ | |||||||
Salaries –officers | 262,670 | 102,000 | ||||||
Pension contributions | 2,769 | 2,040 | ||||||
Fees – Board of Directors | 44,000 | 24,000 | ||||||
Share - based compensation - officers | 2,122 | - | ||||||
Share – based compensation – Board of Directors | 62,241 | - | ||||||
Other benefits – officers | 5,387 | 4,391 | ||||||
Total compensation | 379,189 | 132,431 |
The Company has added three employees in key management amounts in 2020. A balance of $78,524 of key management compensation, of the amounts noted above, is included in accounts payable and accrued liabilities as at March 31, 2020 (December 31, 2019 - $130,604).
18. Financial instruments
As part of its operations, the Company carries a number of financial instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments except as otherwise disclosed. The Company's overall risk management program focuses on the unpredictability of the financial market and seeks to minimize potential adverse effects on the Company's financial performance. The Company does not use derivative financial instruments to hedge these risks.
18
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
18. Financial instruments (continued)
Foreign currency risk
The Company enters into transactions denominated in US dollars for which the related revenues, expenses, accounts receivable and accounts payable and accrued liabilities balances are subject to exchange rate fluctuations.
As at March 31, 2020 the following items are denominated in US dollars:
March 31, 2020 CDN | December 31, 2019 CDN | |||||||
$ | $ | |||||||
Cash | 470,133 | 74,749 | ||||||
Accounts receivable | 52,066 | 28,704 | ||||||
Accounts payable and accrued liabilities | (147,095 | ) | (403,273 | ) | ||||
Total | 375,104 | (299,820 | ) |
Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.
Sensitivity analysis
At March 31, 2020, if the US Dollar changes by 10% against the Canadian dollar with all other variables held constant, the impact on pre-tax gain or loss for the year ended March 31, 2020 would have been $37,000 (December 31, 2019 – $(29,000)).
Credit risk
Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The maximum credit risk to which the Company is exposed as at March 31, 2020 represents the carrying amount of cash, accounts receivable and deposits.
19
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
18. Financial instruments (continued)
Credit concentration
During the year ended March 31, 2020, two customers accounted for 78% (March 31, 2019 – three customers for 61%) of revenues from operations.
Three months ended March 31, 2020 | Three months ended March 31, 2019 | |||||||||||||||
Revenues | % of total revenues | Revenues | % of total revenues | |||||||||||||
$ | % | $ | % | |||||||||||||
Customer 1 | 474,432 | 66 | 210,667 | 29 | ||||||||||||
Customer 2 | 87,945 | 12 | 139,813 | 19 | ||||||||||||
Customer 3 | - | - | 94,077 | 13 | ||||||||||||
Total | 562,377 | 78 | 444,557 | 61 |
Three customers accounted for 51% (December 31, 2019 – one customer for 93%) of trade accounts receivable with amounts owing to the Company of $103,556 (2019 - $96,874), representing the Company's major credit risk exposure. Credit concentration is determined based on customers representing 10% or more of total revenues and/or total accounts receivable. The Company believes that there is no unusual exposure associated with the collection of these receivables. The Company manages its credit risk by performing credit assessments of its customers and provides allowances for potentially uncollectible accounts receivable. The Company does not generally require collateral or other security from customers on accounts receivable.
Fair value of financial instruments
Financial instruments are comprised of cash, accounts receivable, investments, deposits, accounts payable and accrued liabilities, term loans, long-term debt and convertible debentures. There are three levels of fair value that reflect the significance of inputs used in determining fair values of financial instruments:
Level 1 — | quoted prices (unadjusted) in active markets for identical assets or liabilities. |
Level 2 — | inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices). |
Level 3 — | inputs for the asset or liability that are not based on observable market data. |
Investments in BGF shares are valued as at March 31, 2020 at quoted market prices and are classified as Level 1. Investments in BGF shares were valued as at December 31, 2018 based on a valuation technique that estimates a business' value based on a recent round of financing and were classified as Level 3.
Investments in HPQ shares are valued at quoted market prices and are classified as Level 1.
Investments in HPQ warrants are valued using the Black-Scholes pricing model and are classified as Level 3.
20
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
18. Financial instruments (continued)
Fair value of financial instruments - continued
The fair values of cash, accounts receivable, accounts payable and accrued liabilities, and term loans approximate their carrying amounts due to their short-term maturities.
The fair value of the long-term debt and of the 2018 Convertible Debenture approximates their carrying amounts due to their recent issuance.
Interest rate risk
Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. Changes in market interest rates may have an effect on the cash flows associated with some financial assets and liabilities, known as cash flow risk, and on the fair value of other financial assets or liabilities, known as price risk, and on the fair value of investments or liabilities, known as price risks. The Company is exposed to a risk of fair value on the term loans and convertible debentures as those financial instruments bear interest at fixed rates.
Price risk
Price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market price (other than those arising from foreign currency risk and interest risk), whether those changes are caused by factors specific to the individual financial instrument or its issuers or factors affecting all similar financial instruments traded in the market. The most significant exposure to the price risk for the Company arises from its investments in shares of public companies quoted on the TSXV Exchange. If equity prices had increased or decreased by 15% as at March 31, 2020, with all other variables held constant, the Company’s investments would have increased or decreased respectively, by approximately $168,000 (December 31, 2019 - $241,000).
Liquidity risk
Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivery of cash or another financial asset. The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity and / or debt issuances and to generate positive cash flows from operations (see note 1 (b)). The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments.
21
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
18. Financial instruments (continued)
Liquidity risk - continued
The following table summarizes the contractual maturities of financial liabilities as at March 31, 2020:
Carrying value | Total contractual amount | 6 months or less | 6 to 12 months | |||||||||||||
$ | $ | $ | $ | |||||||||||||
Accounts payable and accrued liabilities | 5,278,093 | 5,278,093 | - | - | ||||||||||||
Promissory notes | 295,000 | 295,000 | - | - | ||||||||||||
Term loans | 577,468 | 329,968 | 247,500 | - | ||||||||||||
Convertible debentures | 3,774,356 | 2,785,571 | 42,893 | 945,892 | ||||||||||||
9,924,917 | 8,688,632 | 290,393 | 945,892 |
19. Contingent liabilities
The Company is currently a party to various legal proceedings and a tax authorities’ review. If management believes that a loss arising from these matters is probable and can reasonably be estimated, that amount of the loss is recorded. As additional information becomes available, any potential liability related to these matters is assessed and the estimates are revised, if necessary. Based on currently available information, management believes that the ultimate outcome of these matters, individually and in aggregate, will not have a material adverse effect on the Company’s financial position or overall trends in results of operations.
The Company had received a government grant in prior years of approximately $800,000 to assist with the development of a new system of advanced waste treatment systems technology. The grant is potentially repayable at the rate of 3% of any consideration received as a result of the project, for which funding has been received, to a maximum of the actual grant received. This repayment provision will remain in effect until May 30, 2024. The Company abandoned the project in 2011 and accordingly, no amount is expected to be repaid.
22
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
20. Capital management
The Company’s objectives in managing capital are:
a) | To ensure sufficient liquidity to support its current operations and execute its business plan; and |
b) | To provide adequate return to the shareholders |
The Company’s primary objectives when managing capital is to ensure the entity continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders.
The Company currently funds these requirements from cash flows from operations and with financing arrangements with third parties and shareholders. The Company is not subject to any externally imposed capital requirements.
The management of capital includes common shares, warrants reserve, contributed surplus and equity portion of convertible debentures for a total amount of $54,770,422 (December 31, 2019 - $54,154,733) and debt of $4,358,688, (December 31, 2019 - $3,679,323). The Company monitors its working capital in order to meet its financial obligations. As at March 31, 2020, the Company’s working capital deficiency was $11,157,110 (December 31, 2019 – deficiency of $10,492,101).
There were no changes in the Company’s approach during the three months ended March 31, 2020.
21. Segment information
The Company operates in one segment, based on financial information that is available and evaluated by the Company’s Board of Directors.
The Company’s head office is located in Montreal, Quebec. The operation of the Company is located in one geographic area: Canada. The following is a summary of the Company’s geographic information:
Three months ended March, 31 | ||||||||
2020 | 2019 | |||||||
$ | $ | |||||||
Revenue from external customers | ||||||||
Canada | 121,232 | 113,166 | ||||||
United States | 33,713 | 336,320 | ||||||
Europe | 962 | 215,932 | ||||||
Mexico | - | 32,643 | ||||||
Asia | 475,057 | 38,382 | ||||||
South America | 87,944 | - | ||||||
718,908 | 736,443 |
23
PyroGenesis Canada Inc.
Notes to the Condensed Interim Financial Statements
For the periods ended March 31, 2020 and 2019
(unaudited)
21. Segment information (continued)
The following is a summary of the Company’s revenue by product line:
Three months ended March 31, | ||||||||
2020 | 2019 | |||||||
$ | $ | |||||||
Sales of goods under long-term contracts | 637,950 | 719,125 | ||||||
Sales of goods in point of time | 59,995 | 12,466 | ||||||
Other revenues | 20,963 | 4,852 | ||||||
718,908 | 736,443 |
The Company has entered into long-term leases for premises, computer software, photocopier equipment and automobile. The minimum lease payments due over the next five years are as follows:
22. Subsequent events
The global pandemic due to the novel coronavirus (COVID-19) is a situation that is constantly evolving, and the measures put in place are having multiple impacts on provincial, national and global economies. The overall effect of these events on the Company and its operations is too uncertain to be estimated at this time. The impacts will be accounted for when they are known and may be assessed.
The Company received under the exclusivity contract with DROSRITE International approximately US$3,545,572 between April and July 14, 2020.
The Company received under the exclusivity contract with a US tunneling corporation approximately US$324,917 in April 2020.
On May 26, 2020, the Company completed a share debt transaction with HPQ to settle outstanding trade accounts receivable in the amount of $395,514, for which an amount of $30,002 was included in trade accounts receivable as at December 31, 2019, whereby the Company received 4,394,600 units at a price of $0.09 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each warrant will allow its holder to subscribe to one common share at the price of $0.10 for a period of 36 months from the date of closing. Each share issued pursuant to the debt settlement will have a mandatory four month and one day holding period from the date of closing. This settlement is subject to the approval of the TSX Venture.
In May 2020, the Company issued 120,000 common shares upon the exercise of 120,000 stock options with an exercise price of $0.58, and in June 2020, the Company issued 120,000 common shares upon the exercise of 120,000 stock options with an exercise price of $0.60.
In June 2020, the Company issued 4,045,300 common shares upon the exercise of 3,745,300 share purchase warrants for total proceeds of $3,173,419, and in July 2020, the Company issued 186,000 common shares upon the exercise of 186,000 share purchase warrants for total proceeds of $131,100.
Between April 7, 2020 and June 30, 2020, the Company redeemed 1,285,000 of its common shares for an amount of $964,391.
In June 2020, holders of the outstanding $2,700,000 convertible debenture requested to convert an amount of $2,695,500 into common shares of the Company. The remaining balance of $4,500 was repaid on June 30, 2020.
24